Polypyrpyridylruthenium(II) complexes exert in vitro and in vivo nematocidal activity and show significant inhibition of parasite acetylcholinesterases

Madhu Sundaraned,1, Ramon M. Eichenbergb, Rafid Al-Hallafb, Dai Yangb, Javier Sotillob, Siji Rajan, Phurpa Wangchukb, Paul R. Giacominb, F. Richard Keeneb,c, Alex Loukasb, J. Grant Collinsa,1, Mark S. Pearsonb,∗,1

School of Physical, Environmental and Mathematical Sciences, UNSW (ADFA), Canberra, Australian Capital Territory, 2612, Australia
Centre for Biodiscovery and Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland, 4878, Australia
School of Physical Sciences, University of Adelaide, Adelaide, South Australia, 5005, Australia

ARTICLE INFO

Keywords:
Acetylcholinesterase
Trichuris muris
Ruthenium complex
Antihelminthic

ABSTRACT

Over 4.5 billion people are at risk of infection with soil transmitted helminths and there are concerns about the development of resistance to the handful of frontline nematocides in endemic populations. We investigated the anti-nematode efficacy of a series of polypyrpyridylruthenium(II) complexes and showed they were active against L3 and adult stages of Trichuris muris, the rodent homologue of the causative agent of human trichuriasis, T. trichiura. One of the compounds, Rubb12-mono, which was among the most potent in its ability to kill L3 (IC50 = 3.1 ± 0.4 μM) and adult (IC50 = 5.2 ± 0.3 μM) stage worms was assessed for efficacy in a mouse model of trichuriasis by administering 3 consecutive daily oral doses of the drug 3 weeks post infection with the murine whipworm Trichuris muris. Mice treated with Rubb12-mono showed an average 66% reduction (P = 0.015) in faecal egg count over two independent trials. The drugs partially exerted their activity through inhibition of acetylcholinesterases, as worms treated in vitro and in vivo showed significant decreases in the activity of this class of enzymes. Our data show that ruthenium complexes are effective against T. muris, a model gastro-intestinal nematode and soil-transmitted helminth. Further, knowledge of the target of ruthenium drugs can facilitate modification of current compounds to identify analogues which are even more effective and selective against Trichuris and other helminths of human and veterinary importance.

1. Introduction

More than 4.5 billion people worldwide are at risk of infection by soil-transmitted helminths (STHs) and over one-third of this number are infected with these parasites (Ascaris lumbricoides ~ 0.8 billion infections), whipworm (Trichuris trichiura ~ 0.46 billion) and hookworms (Necator americanus and Ancylostoma duodenale ~ 0.44 billion) (Pullan et al., 2014). STHs are prevalent in more than 100 countries (Gan et al., 2009), particularly in developing tropical and subtropical regions (Sub-Saharan Africa, East Asia and South America) where the hygiene conditions and sanitation practises are poor.

STH infections rarely cause death; rather, they cause chronic and insidious effects on the host’s health with clinical manifestations correlating with infection intensity. Heavy infection causes extensive morbidities such as intestinal disturbances, nutrition loss, physical and intellectual growth retardation and severe anaemia, particularly in pre-and school-aged children (Brooker et al., 1999; Stoltzfus et al., 2000). STH remains a serious problem in public health with a global burden of 4.98 million years lost to disability (YLDs) (Pullan et al., 2014), which approaches that caused by malaria.

Despite the public-health importance of these infections, these diseases have been neglected by the medical and international communities, predominantly because they are concentrated in very poor communities and the diseases can often be overshadowed by other public health or social issues. But, in recent years, the control of STH has become more important in public health management, and combat strategies have been proposed after the World Health Assembly resolution in 2001, with the administration of anthelmintics being the cornerstone of these programmes (Loukas and Bethony, 2008).

Five drugs (albendazole, mebendazole, pyrantel pamoate,
levamisole, and ivermectin) are currently available for the treatment of STH, yet control programmes rely heavily on only the two benzimidazoles (albendazole and mebendazole) because of economical and operational feasibility (Tritten et al., 2011). 

There is no direct evidence for emerging resistance to any of the current anthelmintics in human helminth populations, however, low cure rates have been reported for *T. trichiura* and hookworm infections (Keiser and Utzinger, 2010). Repeated and prolonged administration of these anthelmintics, necessitated by sub-optimal drug efficacies, increases the risk of resistance developing and has already been well documented among nematodes of veterinary importance, and is increasing in frequency as a consequence of extensive use of benzimidazoles over extended periods of time (Kaplan, 2004).

Among potential targets for nematode chemotherapy are acetylcholinesterases (AChEs). These enzymes catalyse the rapid breakdown of the neurotransmitter acetylcholine (ACh) in both central and peripheral nervous systems of eukaryotic organisms, and so control neuronal function (Massoulie et al., 1993). In addition to controlling cholinergic synapses, multiple isoforms of the enzyme are secreted from many nematodes in large amounts and have been implicated in mediating pathogenesis of nematode infection by modulating the host immune system through the disruption of host cholinergic signalling (Selkirk et al., 2005; Vaux et al., 2016) and providing acetate and choline precursors for helminth metabolism (Lee, 1996).

With respect to its termination of synaptic transmission, inhibition of AChE produces an excess accumulation of ACh and overstimulation of its receptors, causing uncoordinated neuromuscular function that often results in death due to respiratory paralysis (Thapa et al., 2017). As such, AChE inhibitors are widely used as pesticides (Kwong, 2002) and anthelmintics (Orhan, 2013). Indeed, metrifonate, an organophosphorus AChE inhibitor originally used as an insecticide, has also been used for the treatment of human and veterinary nematode infections (Thompson et al., 1996) but now has limited use as a therapeutic because of off-target toxicity (Kramer et al., 2014). Moreover, the frontline nematocides all target the neuromusculature of these parasites (Thompson et al., 1996) although they are not necessarily inhibitors of AChE.

In addition to organophosphates, mono-nuclear chemical complexes of the transition metal ruthenium have been shown to target and inhibit enzymes such as AChE (Vyas et al., 2014), and there are numerous recent studies documenting the efficacy of polypyridylruthenium(II) complexes against a variety of different microbial pathogens (Li et al., 2011; Pandrala et al., 2013; Gorle et al., 2014). Unlike their organophosphorus counterparts, ruthenium complexes are speculated to exert their inhibitory effects through a combination of electrostatic and hydrophobic interactions at the peripheral anionic (PAS) site of AChE, which is located at the gate of the enzyme’s catalytic gorge (Bourne et al., 2005), and not through direct interaction with the active site. Ruthenium complexes are thought to be less toxic to human cells than small-molecule inhibitors because of this mode of inhibition and also because the overall neutral charge in the outer membrane leaflet of eukaryotic cells (Mason et al., 2007) creates a greatly reduced capacity for electrostatic interaction with the metal compounds (Gorle et al., 2016).

Herein, we demonstrate the AChE-inhibitory action of two mononuclear and a series of di-, tri- and tetra-nuclear polypyridylruthenium (II) (ruthenium) complexes linked by the bis(4′-methyl-2,2′-bipyridyl)-1,n-alkane ligand (bbn) against extracts of *T. muris* and *Ancylostoma caninum* (helminths used as models of human trichuriasis and hookworm infection, respectively) and both adult and L3 stage *T. muris* parasites in *vitro*. We also show the *in vivo* efficacy of one of these ruthenium complexes (Rubbn mono) in a mouse model of trichuriasis, providing evidence that drugs based on these compounds could be a valuable addition to the chemotherapeutic arsenal against both human and veterinary nematode infections.

2. Materials and methods

2.1. Nomenclature and preparation of ruthenium complexes

\[ \text{[Ru(phen)₂(Me₂bpy)]}^{2+} \quad (\text{phen} = 1,10\text{-phenanthroline}; \text{Me₂bpy} = 4′,4′\text{-dimethyl-2,2′-bipridine}) \] and the mononuclear (Rubbn mono), dinuclear (Rubbn di), trinuclear (Rubbn tri), tetranuclear linear (Rubbn tl) and tetranuclear non-linear (Rubbn tnl) polypyridylruthenium(II) complexes (Fig. 1) were synthesised using the appropriate bis(4′-(4-methyl-2,2′-bipyridyl))-1,n-alkane ligand (bbn) as
previously described (Gorle et al., 2014). All ruthenium complexes were chloride salts and were dissolved in H₂O at stock concentrations of 1 mM.

2.2. Animals and parasites

Six- to eight-week old male B10.BR mice were purchased from the Animal Resource Centre, Canningvale, Western Australia and allowed to acclimatise for one week before infection. Mice were orally infected with 200 μl of PBS containing approximately 200 live embryonated *T. muris* eggs. All animals were kept in groups of 5 mice in cages with free access to water and food and with a 12-h light/dark cycle. Third stage larvae (L3) and adult worms were harvested from the caecum by sacrificing the mice after three weeks and five weeks, respectively. Both stages were washed with PBS containing 2 × antibiotic/antimycotic (AA) and used for either extract preparation (adult) or in vitro experiments (adult and L3).

2.3. Parasite extract preparation

Freshly harvested adult *T. muris* or *A. caninum* (thawed from -80 °C stocks) were homogenised (10 parasites/200 μl) in PBS containing 1% Triton X-100, 40 mM Tris-HCl, pH 7.4, at 4 °C using a TissueLyser II (Qiagen) and the supernatant collected by centrifugation at 15,000 g for 60 min at 4 °C. Protein concentration was determined using the Pierce BCA Protein Assay kit (Thermo Scientific) and absorbance was measured (405 nm) every 10 min for 5 h at 37 °C. Protein extracts was determined in a Polarstar Omega microplate reader (200 μl) in PBS containing 1% Triton X-100-soluble extracts were made from each set of adult and L3 stage parasites.* A. caninum* and *T. muris* eggs. All animals were kept in groups of 5 mice in cages with free access to water and food and with a 12-h light/dark cycle. Third stage larvae (L3) and adult worms were harvested from the caecum by sacrificing the mice after three weeks and five weeks, respectively. Both stages were washed with PBS containing 2 × antibiotic/antimycotic (AA) and used for either extract preparation (adult) or in vitro experiments (adult and L3).

2.4. Enzyme activity in parasite extracts and inhibition assays

AChE activity in Triton X-100-soluble adult *T. muris* and *A. caninum* extracts was determined in a Polarstar Omega microplate reader (200 μl final volume in well-plates) using the Ellman method (Ellman et al., 1961). Extracts were serially diluted (40-10 μg) in AChE assay buffer (0.1 M sodium phosphate, pH 7.4), 2 mM acetyl-thiocholine (AcSch) and 0.5 mM 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB) were added and absorbance was measured (405 nm) every 10 min for 5 h at 37 °C. Specific activity was calculated using the initial velocity of the reaction. For AChE inhibition assays, extract equal to a specific activity of 0.55 nmol/min/well (T. muris - 30 μg, A. caninum – 20 μg) were diluted in AChE assay buffer to a final volume of 170 μl and pre-incubated with ruthenium complexes (10 nM–100 μM) for 20 min at RT. AcSch and DTNB were added at 2 mM and 0.5 mM, respectively and absorbance was measured (405 nm) every 10 min for 5 h at 37 °C. Inhibition for each sample was calculated relative to the negative control (reactions without ruthenium complexes) and reactions were performed in duplicate.

2.5. In vivo activity of ruthenium complexes against adult and L3 stage *T. muris*

Ruthenium complexes were dissolved in sterile PBS for use in the assay. Adult or L3 stage worms were transferred in groups of 4 into each well of a 48-well plate containing 0.5 ml pre-warmed RPMI medium supplemented with 2 × AA and cultured with ruthenium complexes (50 μM). Control worms were treated with the PBS vehicle. All worms were incubated at 37 °C and 5% CO₂ for 72 h and monitored every 24 h for motility by microscopic examination (20 × ). The viability of the worms was evaluated according to previously reported protocols (Tritten et al., 2012; Keiser et al., 2013) using a motility score from 0 to 3 (0 = dead, 1 = very low motility, 2 = low motility, 3 = normal motility). IC₅₀ values of the two most effective ruthenium complexes were then similarly tested at different concentrations ranging from 3.125 to 50 μM. Assays were conducted in duplicate and data is represented as the average of these two experiments ± SE. Albenzadole was used at 200 μg/ml - the IC₅₀ previously determined against adult and L3 stage *T. muris* (Tritten et al., 2011) - as a positive control in all experiments.

2.6. Enzyme inhibition studies on ruthenium complex-treated adult *T. muris*

Groups of five, freshly isolated adult *T. muris* were cultured in the presence of sub-lethal concentrations of either Rubb₁₂-mono and Rubb₁₂-tri (6.25 μM in PBS) or PBS alone in RPMI medium supplemented with 2 × AA. Three sets of five worms were used for each drug tested. Worms were collected after 24 h when they were still motile. Triton X-100-soluble extracts were made from each set of five worms (so, three extracts for each drug tested), quantified using the Pierce BCA Protein Assay kit (Thermofisher) and immediately assayed for AChE activity. Each assay was technically replicated three times. For each enzyme assay, activities of drug-treated parasites were expressed relative to worms cultured without ruthenium complexes (negative control). Data is the average of assays run on triplicate extracts and three technical replicates of each assay ± SE.

2.7. Tolerability study

In order to determine the appropriate dose of Rubb₁₂-mono to be used in the in vivo study, the maximum tolerated dose was determined for the B10.BR mouse strain. Rubb₁₂-mono was administered to groups of three male mice for three consecutive days. The doses ranged from 5 to 20 mg/kg. Animals were closely monitored for adverse clinical signs throughout the study and mice showing adverse effects were euthanised using CO₂ asphyxiation. The highest dose that did not cause any adverse clinical signs for three consecutive daily doses was considered to be the maximum tolerated dose (MTD).

2.8. In vivo efficacy of Rubb₁₂-mono

The in vivo efficacy of Rubb₁₂-mono was tested in two independent trials. For each trial, groups of nine male B10.BR mice (6-8 weeks old) were each orally infected with 200 μl of PBS containing approximately 200 live embryonated *T. muris* eggs. At 28 days p.i., one group was given three consecutive daily oral doses (200 μl) of Rubb₁₂-mono (2 × 10 mg/kg in PBS and 1 × 5 mg/kg in PBS) and the other (negative control group) was given three consecutive daily oral doses (200 μl) of PBS. Mice were sacrificed at 35 days p.i. and worms were harvested from the caecum and counted manually using light microscopy (20 × magnification). The worm burden reduction (WBR) was calculated as: [(a − b)/a] × 100, where a = average worm count in the negative control group and b = average worm count in a treated group. Faecal samples (approximately 0.1 g) from each individual mouse were collected 24 h before necropsy, homogenised in 2 ml of saturated NaCl overnight at 4 °C and the number of eggs counted in triplicate using a Whitlock McMaster counting chamber. This number was used to determine the number of eggs per gram (EPG) of faeces and reduction calculated as for WBR. Extracts were prepared from equal numbers of worms harvested from each individual mouse of each group (trial 1 control – n = 9 mice, trial 1 treatment – n = 6 mice, trial 2 control – n = 9 mice, trial 2 treatment – n = 7 mice) and assayed in triplicate for AChE activity. For each trial, differences in AChE activity was calculated by comparing the average of all extracts from the treatment group with the average (± SE) of all extracts from the control group.

2.9. Statistical analyses

Statistical analyses were performed using Graphpad Prism 7. Inhibition curves and IC₅₀ values were generated using sigmoidal dose-response (variable slope) with a non-linear fit model. One-way ANOVA with Dunn’s multiple comparison was used to determine significance (p), which was set at 0.05. In the case where only two groups were compared (in vivo studies), student’s t-test with Welch’s correction was
3. Results

3.1. Inhibition of AChE activity in adult *T. muris* extracts

A series of ruthenium complexes were screened at 1 μM for AChE inhibitory activity in *T. muris* adult parasite extract. Except for [Ru(phen)(Me2bpy)]²⁺ and Rubb₁₁₀-tri, all complexes inhibited 65-93% AChE activity (Table 1). The IC₅₀ for each ruthenium complex (50 μM) for 24 h. Albendazole was used at 200 μg/ml. Experiments were performed in duplicate and data represents the average of these two experiments ± SE. Significance determined by student’s t-test. *P ≤ 0.05, ***P ≤ 0.001.

| Compound                  | AChE inhibition (%) a, b | IC₅₀ (μM) b |
|---------------------------|--------------------------|-------------|
| [Ru(phen)₂(Me₂bpy)]²⁺     | 0.7 ± 0.6                | 31.26 ± 1.17|
| Rubb-tri                  | 81.6 ± 0.3               | 0.29 ± 0.00 |
| Rubb₁₁₀-tl                | 66.4 ± 0.2               | 1.0 ± 0.05  |
| Rubb₁₁₀-lnl               | 81.2 ± 0.1               | 0.83 ± 0.06 |
| Rubb₁₁₀-tri               | 90.7 ± 0.8               | 0.24 ± 0.01 |
| Rubb₁₁₀-tl                | 76.4 ± 0.7               | 0.47 ± 0.04 |
| Rubb₁₁₀-lnl               | 69.5 ± 0.7               | 0.47 ± 0.04 |
| Rubb₁₁₀-tri               | 91.9 ± 0.0               | 0.25 ± 0.00 |

a Inhibition of AChE activity assessed at 1 μM.
b Data represent the mean of duplicate experiments ± SE.

| Compound                  | AChE inhibition (%) a, b | IC₅₀ (μM) b |
|---------------------------|--------------------------|-------------|
| [Ru(phen)₂(Me₂bpy)]²⁺     | 56.8 ± 0.0               | 0.6 ± 0.0   |
| Rubb-tnl                  | 71.4 ± 1.0               | ND          |
| Rubb₁₁₀-tnl               | 76.6 ± 0.1               | 0.2 ± 0.0   |
| Rubb₁₁₀-tl                | 47.1 ± 0.5               | 0.8 ± 0.0   |
| Rubb₁₁₀-tri               | 58.5 ± 0.1               | 1.0 ± 0.0   |
| Rubb₁₁₀-tnl               | 18.4 ± 3.4               | 18.1 ± 0.2  |
| Rubb₁₁₀-tl                | 57.1 ± 1.0               | 0.8 ± 0.0   |
| Rubb₁₁₀-tri               | 55.4 ± 0.4               | 0.9 ± 0.0   |
| Rubb₁₁₀-tl                | 59.7 ± 0.2               | 0.6 ± 0.0   |
| Rubb₁₁₀-tnl               | 39.4 ± 0.7               | 1.4 ± 0.1   |
| Rubb₁₁₀-tri               | 43.6 ± 0.2               | ND          |
| Rubb₁₁₀-tl                | 37.0 ± 1.0               | 1.0 ± 0.1   |
| Rubb₁₁₀-tnl               | 27.6 ± 2.1               | 3.5 ± 0.3   |

a Inhibition of AChE activity assessed at 1 μM.
b Data represent the mean of duplicate experiments ± SE.

3.2. Inhibition of AChE activity in adult *A. caninum* extracts

Since the ruthenium complexes inhibited AChE activity in *T. muris* extract, we explored the inhibitory activities of the compounds in extracts of *A. caninum* (Table 2). The series displayed a more varied range of activity than was seen for *T. muris*, with AChE inhibition ranging from 18 to 76%. Rubb₁₂-tl and Rubb₁₂-di showed the greatest inhibitory activity against *A. caninum* extracts, with IC₅₀ values of 0.2 ± 0.01 μM and 0.6 ± 0.03 μM, respectively. AChE inhibition increased with increasing nuclearity of the ruthenium centres only to the level of the dinuclear complex, with the inhibition by Rubb₁₁₂-tnl ≈ Rubb₁₁₂-di ≈ Rubb₁₁₂-tri ≈ Rubb₁₁₂-tl. The tetra-linear complexes showed greater activity compared to their non-linear counterparts and the inhibitory activity of the tri-nuclear complexes decreased with increasing chain length of the linking ligand (bbn) (Table 2) (Fig. 2).

| Compound                  | AChE inhibition (%) a, b | IC₅₀ (μM) b |
|---------------------------|--------------------------|-------------|
| [Ru(phen)₂(Me₂bpy)]²⁺     | 56.8 ± 0.0               | 0.6 ± 0.0   |
| Rubb₁₁₀-tnl               | 71.4 ± 1.0               | ND          |
| Rubb₁₁₀-tl                | 76.6 ± 0.1               | 0.2 ± 0.0   |
| Rubb₁₁₀-tri               | 47.1 ± 0.5               | 0.8 ± 0.0   |
| Rubb₁₁₀-tnl               | 58.5 ± 0.1               | 1.0 ± 0.0   |
| Rubb₁₁₀-tnl               | 18.4 ± 3.4               | 18.1 ± 0.2  |
| Rubb₁₁₀-tnl               | 57.1 ± 1.0               | 0.8 ± 0.0   |
| Rubb₁₁₀-tri               | 55.4 ± 0.4               | 0.9 ± 0.0   |
| Rubb₁₁₀-tnl               | 59.7 ± 0.2               | 0.6 ± 0.0   |
| Rubb₁₁₀-tnl               | 39.4 ± 0.7               | 1.4 ± 0.1   |
| Rubb₁₁₀-tri               | 43.6 ± 0.2               | ND          |
| Rubb₁₁₀-tl                | 37.0 ± 1.0               | 1.0 ± 0.1   |
| Rubb₁₁₀-tnl               | 27.6 ± 2.1               | 3.5 ± 0.3   |

a Inhibition of AChE activity assessed at 1 μM.
b Data represent the mean of duplicate experiments ± SE.
other complexes killed 100% of the worms after 48 h (data not shown). Subsequently, the most active complexes, Rubb₁₂-mono and Rubb₁₂-tri, were tested at different concentrations against L₃ stage worms and displayed IC₅₀ values of 3.1 ± 0.4 and 2.3 ± 0.3 μM, respectively (Table 3). In identical experiments with adult parasites, Rubb₁₂-mono and Rubb₁₂-tri were the most effective, killing 100% of adult worms in 24 h (Fig. 4). IC₅₀ values were subsequently determined as 3.1 ± 0.4 and 2.3 ± 0.3 μM, respectively (Table 3).

### 3.4. Mechanism of action of ruthenium complexes against T. muris

Given the AChE inhibitory effect exhibited by ruthenium complexes against adult parasite extracts and their efficacy in anti-Trichuris assays in vitro, their mechanism of action was analysed in live adult worms. Extracts made from parasites cultured for 24 h in the presence of sub-lethal concentrations of Ruthenium complexes were tested against both L₃ and adult T. muris) were assayed for AChE activity, and significant reductions were seen in the treated worms (Rubb₁₂-mono - 42%, P < 0.0001; Rubb₁₂-tri - 44%, P < 0.0001) compared to controls (Fig. 5).

### 3.5. Tolerability of Rubb₁₂-mono

The tolerability of Rubb₁₂-mono in mice was evaluated using consecutive daily oral doses of 5, 10 and 20 mg/kg. According to standard practice, the MTD was considered to be the highest dose where no signs of physical stress were observed. Rubb₁₂-mono was not tolerated at 20 mg/kg (1 out of 3 mice died within 15 min) but did not show any toxicity at 10 mg/kg, even after three consecutive oral doses. The MTD of Rubb₁₂-mono was considered to be 10 mg/kg and was used as the dose in the in vivo efficacy study.

Based on the significant in vitro activity against T. muris adults and L₃ stage worms, Rubb₁₂-mono was further assessed for its in vivo efficacy using a mouse model of T. muris infection. Three weeks after infection, Rubb₁₂-mono was orally administered once daily for 2 days at 10 mg/kg with a 5 mg/kg dose administered on the third day. Worm and faecal egg counts were assessed at 5 weeks post-infection. For trial 1, Rubb₁₂-mono-treated mice achieved significant reductions in worm burden (35%, P = 0.0396) and egg (82%, P = 0.0034) counts, compared to PBS treated controls. Further, extracts made from worms recovered from treated mice showed significantly less AChE activity (P = 0.0044) than extracts from worms recovered from control animals. There was a non-significant decrease (11%, P = 0.279) in the worm burden of Rubb₁₂-mono-treated mice in trial 2 compared to controls and no difference in the AChE activity of extracts made from worms recovered from treated and control mice. However, the faecal egg count seen in treated mice was significantly lower (50%, P = 0.0155) than control animals from this trial. Over the two independent trials, the average reduction in faecal egg count was 66% (P = 0.015), compared to controls.

### 3.6. In vivo efficacy of Rubb₁₂-mono against T. muris

Over 1.5 billion people are infected with soil-transmitted helminths (STHs), no anti-STH vaccines are available and there is evidence that resistance to the handful of drugs used to control this scourge is developing. In this study, we have investigated the activity of a series of ruthenium complexes against two model species of STHs - T. muris and A. caninum - have shown that these compounds are capable of inhibiting AChE activity in extracts made from the parasites and, at least for T. muris, the nematocidal action of ruthenium complexes could be partially due to AChE inhibition, an enzyme vital to the neuromuscular function of these helminths.

With regard to the AChE-inhibitory properties of ruthenium complexes against parasite extracts, no specific relationship between compound structure and activity was observed with T. muris extracts, although all the ruthenium complexes inhibited AChE activity at sub-micromolar to micromolar concentrations with specific tri- and tetranuclear complexes displaying the most potent activity. Conversely, a structure/activity relationship was observed for tetra-nuclear ruthenium complex inhibition of A. caninum extracts, with potency increasing with decreasing chain length between the ruthenium centres. The mononuclear ruthenium complexes are thought to interact with the...
PAS of AChE located at the rim of the active-centre gorge through a combination of electrostatic and hydrophobic interactions (Meggers, 2009). The tri- and tetra-nuclear complexes showed greater activity compared to mononuclear complexes, presumably due to the presence of the flexibly-linked multiple metal centres which may provide more interactions (electrostatic and hydrophobic) with the PAS, or each individual centre may contribute non-specific additional points of contact. That the activity of the ruthenium complexes varied between *T. muris* and *A. canium* extracts is likely due to differences in enzyme orthologues and the existence of multiple isoforms of AChE which are present in different helminth species (Arnon et al., 1999; Selkirk et al., 2005).

Encouraged by the activity of ruthenium complexes in *T. muris* adult parasite extracts, their effect against the L3 and adult stages in vitro were examined. With minor differences in sensitivity, Rubb12-mono and Rubb12-tri showed excellent activity against both stages of the parasite with both complexes exhibiting dose-dependent lethal effects. However, the results of motility experiments did not correlate with inhibition of enzyme activity in worm extracts, especially with Rubb12-mono, which was one of the most effective compounds against both L3 and adult parasites, but not with regards to inhibiting AChE activity in extracts. This is possibly due to the differential accessibility of inhibitor to enzyme in an extract preparation compared to a living parasite. Another explanation is that the mechanism of action of ruthenium complexes is multi-faceted and not just confined to AChE inhibition. AChE activity significantly decreased in extracts made from cultured worms after treatment with sub-lethal concentrations of Rubb12-mono and Rubb12-tri ruthenium complexes, suggesting that ruthenium complexes are active against *T. muris* through AChE inhibition, but the possibility of the compounds exerting their nematocidal activity through interaction with other targets cannot be discounted given their documented ability to interact with molecules other than AChE, such as protein and lipid kinases (Meggers, 2009). There are numerous reports in the literature documenting the development of drug resistance in parasites due to mutation of the compound's target molecule (for example, benzamidazole resistance in nematodes due to single nucleotide polymorphisms in β-tubulin (Von Samson-Himmelstjerna et al., 2007) and mutation of a schistosome sulfotransferase resulting in resistance to oxamniquine (Valentim et al., 2013), and so the use of a drug that is directed against multiple molecular targets may decrease the chance of resistance evolving.

Rubb12-mono was one of the most effective compounds with regards to *in vitro* anti-*Trichuris* activity and was therefore tested for efficacy in a mouse model of *Trichuris* infection. Surprisingly, Rubb12-mono was found to be more toxic by oral administration than what has been reported for simple polypyridylruthenium complexes (eg: [Ru(phen) 3]2+ ) (Brandt et al., 1994). This is probably due to a higher rate of absorption of Rubb12-mono from the intestine into the blood. The complex showed promising *in vivo* activity at tolerated doses in mice, with treatment resulting in reductions in worm (only significant in trial 1) and egg counts (significant in both trials), compared to controls. Rubb12-mono-treated mice in trial 2 had a significantly higher worm load than those in trial 1 and this may explain the reduced efficacy of Rubb12-mono in the repeat trial. Regardless of the variation in parasite load, reduction in egg count was not only significant in both trials but also more pronounced than worm decrease, implying that egg count reduction was not just concomitant with worm burden reduction and that Rubb12-mono treatment affected parasite maturation and fecundity. Further, parasites recovered from Rubb12-mono-treated mice showed significantly decreased AChE activity than those harvested from control mice (consistent with *in vitro* results), suggesting that nematocidal activity was a result of drug-induced inhibition of enzyme activity. Since reductions in both worm and egg counts are required for efficacy of anthelmintics, the *in vivo* results suggest the potential of Rubb12-mono as a drug lead for the development of novel nematocides to reduce infection pathology and interrupt disease transmission. Further, due to the uniquely shared neurobiology of helminths compared with higher eukaryotes (Thompson et al., 1996), we believe ruthenium complexes could exert broad spectrum anthelmintic activity while being relatively non-toxic and, due to the modular nature of these compounds, these drugs could be tailored to target specific regions of molecules, further enhancing their activity and selectivity.

References
Arnon, R., Silman, I., Tarrab-Hashdai, R., 1999. Acetylcholinesterase of Schistosoma mansoni-functional correlates. Contributed in honor of Professor Hans Neurath's 90th birthday. Protein Sci. 8, 2553–2561.
Bourne, V., Radic, Z., Kolb, H.C., Sharpless, K.B., Taylor, P., Marchot, P., 2005. Structural insights into conformational flexibility at the peripheral site and within the active center gorge of AChE. Chem. Biol. Interact. 157–158, 159–165.
Brandt, W.W., Dwyer, F.P., Gyarfas, E.D., 1954. Chelate complexes of 1,10-phenanthroline and related compounds. Chem. Rev. 54, 909-1017.
Brooker, S., Peshu, N., Warn, P.A., Mosobo, M., Guyatt, H.H., Marsh, K., Snow, R.W., 1999. The epidemiology of hookworm infection and its contribution to anaemia among pre-school children on the Kenyan coast. Trans. R. Soc. Trop. Med. Hyg. 93, 240-246.
Ellman, G.L., Courtney, K.D., Andres Jr, V., Feather-Stone, R.M., 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88-95.
Gan, W., Deng, L., Yang, C., He, Q., Hu, J., Yin, H., Jin, X., Lu, C., Wu, Y., Peng, L., 2009. An anticoagulant peptide from the human hookworm, *Ancylostoma duodenale* that inhibits coagulation factors Xa and Xla. FEBS Lett. 583, 1976–1980.
Gorle, A.K., Fetei, M., Warner, J.M., Wallace, L., Keene, F.R., Collins, J.G., 2014. Tri- and tetra-nuclear poly(phenylruthenium)(II) complexes as antimicrobial agents. Dalton Trans. 43, 16713–16725.
Gorle, A.K., Li, X., Primrose, S., Li, F., Fetei, M., Kinobe, R.T., Heimann, K., Warner, J.M., Keene, F.R., Collins, J.G., 2016. Oligonuclear poly(pyridylruthenium(II)) complexes: selectivity between bacteria and eukaryotic cells. J. Antimicrob. Chemother. 71, 1547–1555.
Kaplan, R.M., 2004. Drug resistance in nematodes of veterinary importance: a status...
Keiser, J., Tritten, L., Silbereisen, A., Speich, B., Adelphi, R., Vargas, M., 2013. Activity of oxantel pamoate monotherapy and combination chemotherapy against Trichuris muris and hookworms: revival of an old drug. PLoS Negl. Trop. Dis. 7, e2119.

Keiser, J., Utzinger, J., 2010. Chapter 8—the drugs we have and the drugs we need against major helminth infections. In: Xiao-Nong Zhou, R.B.R.O., Jürg, U. (Eds.), Advances in Parasitology. Academic Press, pp. 197–230.

Kramer, C.V., Zhang, F., Sinclair, D., Olliaro, P.L., 2014. Drugs for treating urinary schistosomiasis. Cochrane Database Syst. Rev. 6 CD000053.

Kwong, T.C., 2002. Organophosphate pesticides: biochemistry and clinical toxicology. Ther. drug Monit. 24, 144–149.

Lee, D.L., 1996. Why do some nematode parasites of the alimentary tract secrete acetylcholinesterase? Int. J. Parasitol. 26, 499–508.

Li, F., Mulyana, Y., Feterl, M., Warner, J.M., Collins, J.G., Keene, F.R., 2011. The antimicrobial activity of inert oligonuclear polypyridylruthenium(II) complexes against pathogenic bacteria, including MRSA. Dalton Trans. 40, 5032–5038.

Loukas, A., Bethony, J.M., 2008. New drugs for an ancient parasite. Nat. Med. 14, 365–367.

Mason, A.J., Marquetter, A., Chebbinger, B., 2007. Zwitterionic phospholipids and sterols modulate antimicrobial peptide-induced membrane destabilization. Biophys. J. 93, 4289–4299.

Massoulie, J., Pezzementi, L., Bon, S., Krejci, E., Vallette, F.M., 1993. Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 41, 31–91.

Meggers, E., 2009. Targeting proteins with metal complexes. Chem. Commun. (Camb) 1001–1010.

Orhan, I.E., 2013. Nature: a substantial source of auspicious substances with acetylcholinesterase inhibitory action. Curr. Neuropharmacol. 11, 379–387.

Pandrila, M., Li, F., Feterl, M., Mulyana, Y., Warner, J.M., Wallace, L., Keene, F.R., Collins, J.G., 2013. Chlorido-containing ruthenium(II) and iridium(III) complexes as antimicrobial agents. Dalton Trans. 42, 4686–4694.

Pullan, R.L., Smith, J.L., Jasrasaria, R., Brooker, S.J., 2014. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. Parasit. Vectors 7, 37.

Selkirk, M.E., Lazari, O., Matthews, J.B., 2005. Functional genomics of nematode acetylcholinesterases. Parasitology (131 Suppl. 1), S3–S18.

Stoltzfus, R.J., Chwaya, H.M., Montresor, A., Albonico, M., Savioli, L., Tielsch, J.M., 2000. Malaria, hookworms and recent fever are related to anaemia and iron status indicators in 0- to 5-y old zanzibari children and these relationships change with age. J. Nutr. 130, 1724–1733.

Thapa, S., Lu, M., Xu, H., 2017. Acetylcholinesterase: a primary target for drugs and insecticides. Mini Rev. Med. Chem. 17, 1665–1676.

Thompson, D.P., Klein, R.D., Geary, T.G., 1996. Prospects for rational approaches to anthelmintic discovery. Parasitology (113 Suppl. 1), S217–S238.

Tritten, L., Silbereisen, A., Keiser, J., 2011. In vitro and in vivo efficacy of Monepantel (AAD 1566) against laboratory models of human intestinal nematode infections. PLoS Negl. Trop. Dis. 5, e1457.

Tritten, L., Silbereisen, A., Keiser, J., 2012. Nitazoxanide: in vitro and in vivo drug effects against Trichuris muris and Ancylostoma caninum, alone or in combination. Int. J. Parasitol. Drugs Drug Resist 2, 98–105.

Vaux, R., Schoeller, C., Berkache, R., Roberts, L.B., Hagen, J., Gounaris, K., Selkirk, M.E., 2016. Modulation of the immune response by nematode secreted acetylcholinesterase revealed by heterologous expression in Trypanosoma musculi. PLoS Pathog. 12, e1005998.

Vyas, N.A., Bhat, S.S., Kumbhar, A.S., Sonawane, U.B., Jani, V., Joshi, R.R., Ramteke, S.N., Kulikarni, P.P., Joshi, B., 2014. Ruthenium(II) polypyridyl complex as inhibitor of acetylcholinesterase and Abeta aggregation. Eur. J. Med. Chem. 75, 375–381.